MedPath

A randomized controlled clinical trial of Qingdai(indigo naturalis) in the treatment of mild to moderate active ulcerative colitis

Phase 1
Recruiting
Conditions
ulcerative colitis
Registration Number
ITMCTR2000003772
Lead Sponsor
Shuguang Hospital affiliated to Shanghai University of traditional Chinese Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

(1) it accords with the diagnostic standard of western medicine for ulcerative colitis.
(2) the selected patients were mild to moderate ulcerative colitis (total Mayo score = 310).
(3) 18-65 years old; regardless of sex.
(4) agree to participate in this study and sign the informed letter at the same time.

Exclusion Criteria

(1) Patients with infectious colitis such as bacillary dysentery, amoebic dysentery, chronic schistosomiasis, intestinal tuberculosis, Crohn's disease, ischemic enteritis and radiation enteritis.
(2) Patients with serious complications such as local stenosis, intestinal obstruction, intestinal perforation, toxic colonic dilatation, massive hemorrhage, colon cancer, rectal cancer.
(3) Patients with other primary and secondary infectious diseases, such as cholecystitis, pneumonia, etc.
(4) Patients with serious diseases of cardiovascular, hepatobiliary, lung, kidney and blood system.
(5) Women during pregnancy and lactation.
(6) Patients with disabilities prescribed by law (blindness, deafness, mute, mental retardation, physical disability).
(7) Patients with severe ulcerative colitis (Mayo=11~12 score); or patients with complications.

Study & Design

Study Type
Interventional study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Total Mayo score;Mayo endoscopic score;
Secondary Outcome Measures
NameTimeMethod
TCM syndrome integral;ESR;Intestinal mucosal histopathology;Fecal calcitonin;C-reactive protein;
© Copyright 2025. All Rights Reserved by MedPath